Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies

Syed Faraz Ahmed; Ahmed A. Quadeer; Matthew R. McKay

. CC-BY-NC 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.03.933226 doi: bioRxiv preprint The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.03.933226 doi: bioRxiv preprint Tables Table S1 : List of GISAID accession IDs for 80 genomic sequences of SARS-CoV-2. Table S2 : List of all SARS-CoV-derived T cell epitopes determined using positive MHC binding assays (with associated MHC allele information available at 4-digit resolution) and found to be identical in SARS-CoV-2. Table S3 : Distribution of all SARS-CoV-derived T cell epitopes obtained using positive MHC binding assays (with associated MHC allele information available at 4-digit resolution) and that are identical in SARS-CoV-2. Table S4 : Set of the SARS-CoV-derived S and N protein T cell epitopes (obtained using positive MHC binding assays) that are identical in SARS-CoV-2 and that maximize estimated population coverage in China (86 distinct epitopes). Table S5 : Estimated global and Chinese population coverages for the individual SARS-CoV-derived S or N protein T cell epitopes (obtained using positive MHC binding assays) that are identical in SARS-CoV-2. Table S6 : SARS-CoV-derived linear B cell epitopes, excluding those in S and N proteins, that are identical in SARS-CoV-2. . CC-BY-NC 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.03.933226 doi: bioRxiv preprint